ATRIUM THERAPEUTICS INC

Atrium Therapeutics has received FDA authorization to start a phase 1/2 clinical trial of the siRNA drug ATR 1072 for the treatment of PRKAG2 syndrome. About 37 participants are planned in two parts: ascending dose cohorts (part A) and a single‑arm expansion cohort to assess safety and signals of efficacy on cardiac structure and function (part B). Clinical sites are being activated, the first patient is expected by the end of 2026, and a proof‑of‑concept signal is targeted for the second half of 2027. The company focuses on RNA therapeutics for cardiomyopathies; the pipeline also includes ATR 1086 and two discovery projects. A balance‑sheet analysis cites a market capitalization of USD 209 million and more cash than debt, and the stock is rated as undervalued. » More on de.investing.com

Atrium Therapeutics has received a $15 million milestone payment from Bristol Myers Squibb after delivering a development candidate for a cardiac RNA-based therapeutic. The collaboration targets discovery, development and commercialization of RNA therapies for cardiovascular diseases; Bristol Myers Squibb will assume future clinical development, regulatory approval and commercialization. Under the agreement, Atrium can receive up to about $1.35 billion in R&D milestones, up to about $825 million in commercial milestones and tiered royalties in the low double-digit percentage range. The payment is intended to support further development of Atrium’s RNA delivery platform for cardiology indications. » More on de.investing.com